Aggregated low density lipoprotein induces tissue factor by inhibiting sphingomyelinase activity in human vascular smooth muscle cells

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 12, 2009, Pages 2137-2146

  Camino Lopez S ^a   Badimon, L ^a,b   Gonzalez A ^a   Canals, D ^c   Pena E ^a   Llorente Cortes V ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

Author keywords

Aggregated LDL; Rho A; Sphingomyelinases; Tissue factor; Vascular smooth muscle cells

Indexed keywords

LOW DENSITY LIPOPROTEIN; RHO KINASE; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOPLASTIN;

ARTICLE; BIOSYNTHESIS; CYTOLOGY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

HUMANS; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RHO-ASSOCIATED KINASES; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOPLASTIN; UP-REGULATION;

EID: 77449109210     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03638.x     Document Type: Article

References (40)

1. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
2. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82: II47-59.
3. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
4. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139: 205-22.
5. Guyton JR, Klemp KF, Mims MP. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J Lipid Res 1991; 32: 953-62.
6. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-9.
7. Camino-Lopez S, Llorente-Cortes V, Sendra J, Badimon L. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 2007; 73: 208-16.
8. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1607-15.
9. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98: 1455-64.
10. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 1998; 273: 9681-7.
11. Loidl A, Sevcsik E, Riesenhuber G, Deigner HP, Hermetter A. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. J Biol Chem 2003; 278: 32921-8.
12. Jeong T, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998; 101: 905-12.
13. Byers DM, Morgan MW, Cook HW, Palmer FB, Spence MW. Niemann-Pick type II fibroblasts exhibit impaired cholesterol esterification in response to sphingomyelin hydrolysis. Biochim Biophys Acta 1992; 1138: 20-6.
14. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 2002; 531: 38-46.
15. Galvan C, Camoletto PG, Cristofani F, Van Veldhoven PP, Ledesma MD. Anomalous surface distribution of glycosyl phosphatidyl inositol-anchored proteins in neurons lacking acid sphingomyelinase. Mol Biol Cell 2008; 19: 509-22.
16. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276: 20589-96.
17. Liu P, Anderson RG. Compartmentalized production of ceramide at the cell surface. J Biol Chem 1995; 270: 27179-85.
18. Bilderback TR, Grigsby RJ, Dobrowsky RT. Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J Biol Chem 1997; 272: 10922-7.
19. Veldman RJ, Maestre N, Aduib OM, Medin JA, Salvayre R, Levade T. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem J 2001; 355: 859-68.
20. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Costales P, Badimon L. Cholesteryl esters of aggregated LDL are internalized by selective uptake in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006; 26: 117-23.
21. Llorente-Cortes V, Otero-Vinas M, Hurt-Camejo E, Martinez-Gonzalez J, Badimon L. Human coronary smooth muscle cells internalize versican-modified LDL through LDL receptor-related protein and LDL receptors. Arterioscler Thromb Vasc Biol 2002; 22: 387-93.
22. Llorente-Cortes V, Otero-Vinas M, Sanchez S, Rodriguez C, Badimon L. Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 2002; 106: 3104-10.
23. Lovat PE, Di Sano F, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004; 96: 1288-99.
24. Weerheim AM, Kolb AM, Sturk A, Nieuwland R. Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem 2002; 302: 191-8.
25. Merrill AH Jr, Liotta DC, Riley RT. Fumonisins: fungal toxins that shed light on sphingolipid function. Trends Cell Biol 1996; 6: 218-23.
26. Cheng ZJ, Singh RD, Sharma DK, Holicky EL, Hanada K, Marks DL, Pagano RE. Distinct mechanisms of clathrin-independent endocytosis have unique sphingolipid requirements. Mol Biol Cell 2006; 17: 3197-210.
27. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 2000; 97: 5895-900.
28. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci U S A 1966; 55: 366-9.
29. Zumbansen M, Stoffel W. Neutral sphingomyelinase 1 deficiency in the mouse causes no lipid storage disease. Mol Cell Biol 2002; 22: 3633-8.
30. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, Kobayashi T, Domae N, Mimori T, Bloom ET, Okazaki T, Umehara H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202: 249-59.
31. Zhang W, Bogdanov M, Pi J, Pittard AJ, Dowhan W. Reversible topological organization within a polytopic membrane protein is governed by a change in membrane phospholipid composition. J Biol Chem 2003; 278: 50128-35.
32. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100: 2276-85.
33. Van Der Geer P. Phosphorylation of LRP1: regulation of transport and signal transduction. Trends Cardiovasc Med 2002; 12: 160-5.
34. Gaultier A, Salicioni AM, Arandjelovic S, Gonias SL. Regulation of the composition of the extracellular matrix by low density lipoprotein receptor-related protein-1: activities based on regulation of mRNA expression. J Biol Chem 2006; 281: 7332-40.
35. Pocivavsek A, Mikhailenko I, Strickland DK, Rebeck GW. Microglial low-density lipoprotein receptor-related protein 1 modulates c-Jun N-terminal kinase activation. J Neuroimmunol 2009; 214: 25-32.
36. Zhong S, Johnson DL. The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits. Proc Natl Acad Sci U S A 2009; 106: 12682-7.
37. Lepine S, Sulpice JC, Giraud F. Signaling pathways involved in glucocorticoid-induced apoptosis of thymocytes. Crit Rev Immunol 2005; 25: 263-88.
38. Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr 2005; 37: 143-53.
39. Deigner HP, Claus R, Bonaterra GA, Gehrke C, Bibak N, Blaess M, Cantz M, Metz J, Kinscherf R. Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis. FASEB J 2001; 15: 807-14.
40. Llorente-Cortes V, Otero-Vinas M, Berrozpe M, Badimon L. Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur J Clin Invest 2004; 34: 182-90.